The purpose of this study was to systematically review all published cases of LGMS in the extremities to provide more demographics as well as clinic-pathologic information on this rare tumor entity. Additionally, we presented the surgical management of a 28y/o patient with the rare case of LGMS of the thumb. Due to the rarity of this tumor, the knowledge is mainly based on case reports or case series resulting in limited statistical significance concerning epidemiology, demographics, clinical characteristics and treatment efficacy [1, 3, 9]. Nevertheless, case report meta-analyses might help improving the clinical practice in the context of rare diseases and provide more information to guide clinicians and surgeons to appropriate treatment [21]. Here we summarized case series and case reports concerning LGMS of the extremities in a quantitative manner.
We have identified and summarized 34 cases. Similar to other locations being published before, there is no distinct age preference, even though the majority of patients was < 60 years old (75%) with a roughly equal gender incidence. Minimal gender differences seen in other publications most likely reflect the limited sample size for examination of this rare tumor. In this systematical review, 23% of LGMS in the extremities presented with a local recurrence. Initially, the painless tumor is often misdiagnosed as a benign lesion and incomplete resection with residual tumor cells leads to local recurrence, just as in the case presented. Many cases do not give any information on the resection margins or the initially suspected diagnosis. Like in our case report and case no. 22 (Tabl. 2) the tumor initially was excised under local anesthesia because a benign lesion was suspected. The tumor recurred after 2 months. The fact that local recurrence was seen only a few months after resection suggests an incomplete initial resection. Literature proposed that recurrent tumor can easily lead to distant metastases and theoretically can dedifferentiate (case 32) [22]. Unfortunately, most published literature mainly focused on reporting pathological studies. That is why information concerning exact surgical procedure is missing. In our opinion, the type of surgical resection (local resection without a margin, marginal resection, wide resection) seems to be important to prevent local recurrence. Another limitation of this review is the different or missing follow-up times in the cases ranging from 4 months up to five years (Tabl. 2). Chan et al. (2017) noticed a significantly different tumor size comparing head and neck LGMS and non-head and neck LGMS having a significantly greater number of cases with tumor size > 4 cm [3]. Non-head and neck tumors were present in the abdomen and pelvis or extremities allowing the tumor to grow silently before symptoms presented. Tumors in the head and neck region are easier visible leading to early diagnose and therapy. LGMS presenting in the extremities also often showed a local recurrence in cases of the tumor size > 4 cm (Tabl. 2). However, we think that not only tumor size and time until therapy, but also surgical procedure is a limiting factor for local recurrence.
LGMS of the hand, especially of the thumb, needs to be distinguished from other tumorous lesions of the extremities because of the proximity of anatomical structures and thus narrow resection margins with the need of a consecutive tissue reconstruction.
Only two case reports describe the incidence of LGMS in the hand (Tabl. 2). We performed a two-stage surgical intervention to secure tumor-free margins. The presented Holevich’s neuro vascular flap is a common and a reliable choice at this anatomical region in order to simultaneously provide the defect coverage and the preserving local sensibility without compromising surgical oncologic principles. The most important aspect for flap survival is a careful pedicle preparation, elevation and prevention of the pedicle strangulation. As presented in the study of San Miguel et al. an amputation also is also a feasible surgical option, leading to a functional loss and an aesthetic impairment [16]. Whenever possible in younger patients, limb salvage should be the first option. Unfortunately, data are sparse concerning the clinical outcome and the patient satisfaction. In the year of 2011 Puhaindran et al. investigated 23 patients in a retrospective study indicating that clinical outcome (regarding surgical management for malignant tumors of the thumb) lead to similar results comparing patients with a thumb amputation at the interphalangeal joint and a thumb-sparing wide excision with reconstruction [23]. Nevertheless, especially younger patients decline amputation. Sarcoma surgery and consecutive flap reconstruction can achieve a high survival rate and a low recurrence rate at any tumor site [24].
Uniform diagnostic criteria using MRI and histopathological evaluation for this rare tumor entity have not yet been well-established. Nevertheless, preoperative MRI is important to avoid an unnecessarily aggressive surgery and to differentiate from a benign lesion even if MR features are nonspecific [25]. A definitive diagnosis is challenging and requires both histopathological and immunohistochemical analyses. The determination of the grade of anaplasia in each tumor is difficult because of wide ranges of histologic features [7, 26]. Incision biopsy is therefore needed to obtain proper diagnosis and justify invasiveness of the surgical management. In cases of a small tumor size, excision biopsy should only be performed if a complete resection with tumor-free margins seems possible, to lower the risk of local recurrence [7, 27]. This suggestion is based on the experiences with other tumor entities and presented case reports without adequate sample size to accurately assess this. Concerning an LGMS we recommend a follow-up care with a regular screening. In the first year there should be a check-up every 4 months, followed by a 6-months interval until the fourth year and finally once a year until 10 years after surgery with local MRI and X-ray of the chest. There is no evidence for pre- or postoperative radiotherapy or chemotherapy [22, 27, 28]. Individual adjuvant or neoadjuvant options should only be evaluated interdisciplinary with a board votum when complete resection of tumor mass is not possible. The prognosis of the tumor may depend upon many factors like the tumor size, staging, site as well as health status of the patient, even if any evidence of this recommendation in studies is missing.